

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 27, 2003, 18:02:45 ; Search time 71 Seconds

(without alignments)
666.253 Million cell updates/sec

Title: US-09-922-895-1

Perfect score: 1854
Sequence: 1 MTSLSDFETFTSTYDYD.....LERTSVSPSTAEPLSIVF 355

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 08
Maximum Match 1008

Listing first 45 summaries

Database :

1: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1854	100.0	355	17	AAW03377
2	1854	100.0	355	18	AAW31850
3	1854	100.0	355	19	AAW27124
4	1854	100.0	355	18	AAW51745
5	1854	100.0	355	22	AAE80109
6	1854	100.0	355	23	AAE15320
7	1851	99.8	355	17	AAW03376
8	1851	99.8	355	18	AAW10100
9	1851	99.8	355	23	ABB07733
10	1851	99.8	355	23	ABB07240

11	1847	99.6	355	22	ABB56341
12	1846	99.6	355	19	AAW51744
13	1826.5	98.5	356	18	AAW25943
14	1781	96.1	355	17	AAW03378
15	1781	96.1	355	19	AAW51745
16	1746	94.2	332	23	ABJ03698
17	1717	92.6	355	23	ABB79520
18	1181.5	63.7	355	15	AAW52749
19	1181.5	63.7	355	18	AAW26588
20	1181.5	63.7	355	18	AAW25751
21	1181.5	63.7	355	21	AAW20571
22	1115.5	60.2	355	18	AAW29179
23	1045	56.4	295	22	AAW80106
24	948	51.1	352	22	AAW79089
25	947	51.1	360	16	AAW79166
26	947	51.1	360	18	AAW5833
27	947	51.1	360	22	AAW80108
28	947	51.1	360	22	AAW07614
29	946	51.0	360	22	AAW07613
30	943.5	50.9	352	18	AAW27125
31	941	50.8	360	22	AAW56340
32	939.5	50.7	371	19	AAW23834
33	938.5	50.6	352	18	AAW27407
34	938.5	50.6	352	18	AAW27123
35	938.5	50.6	352	19	AAW23835
36	938.5	50.6	352	20	AAW88232
37	938.5	50.6	352	22	AAW80111
38	938.5	50.6	352	22	AAW82948
39	938.5	50.6	352	22	AAW83354
40	938.5	50.6	352	22	AAW04321
41	938.5	50.6	352	23	ABB08343
42	938.5	50.6	352	23	AAW52828
43	938.5	50.6	439	20	AAW41280
44	937.5	50.6	352	22	AAW07039
45	937.5	50.6	352	22	AAW07048

ALIGNMENTS

RESULT 1	AAW03377	standard; Protein; 355 AA.
ID	AAW03377	
XX	AAW03377;	
AC		
XX		
DF	15-NOV-1996	(first entry)
XX		
DE	CC-chemokine receptor 3.	
XX		
KW	CC-chemokine receptor 3; CRP-3; Bos-12; Inhibitor; antisense; antiinflammatory; eosinophil.	
XX		
OS	Homo sapiens.	
XX		
FH	Key	Location/Qualifiers
FT	Region	130..138
FT		/note="amino acids 130-138 comprise a motif conserved among C-X-C and C-C chemokine receptors"
FT		
XX		
PN	W09622371-A2.	
XX		
PD	25-JUL-1996.	
XX		
PF	19-JAN-1996;	96WO-US00608.
XX		
PR	19-JAN-1995;	95US-0375199.
XX		
PA	(BGHM) BRIGHAM & WOMENS HOSPITAL.	
PA	(CHIL-) CHILDRENS MEDICAL CENT.	
XX	(LEBK-) LEUKOSITE INC.	
XX		

Non-endogenous hum
Human C-C chemokine
Human CCR3 chemok
CC-chemokine recep
Human C-C chemokif
Human ovary specif
Monkey C-C chemok
C-C chemokine rece
Human MIP-1 alpha/R
Human MIP-1alpha/R
Human CC-chemokine
Rat CC chemokine r
Human CCR1 protein
Amino acid sequenc
Human monocyte che
Human monocyte che
Human CCR2b protel
Human wild-type CC
Human CCR2-641 pol
Macaque chemokine
Non-endogenous hum
Human CC chemokine
Human CCR5. Homo
Human chemokine re
Human CC chemokine
HIV-1 co-receptor
Human CCR5 protein
Human HIV-1 co-rec
Human CCR5 protein
Human chemokine re
Human chemokine (C
Human CC chemokine
Fusion protein con
Human G-protein ch
Human G-protein ch

PI Gerard CJ, Gerard NP, Mackay CR, Ponath PD, Post TW,
 PI Oln S;
 XX WPI; 1996-354528/35.
 DR N-PSDB; AAW31335.
 XX
 PT Mammalian chemokine receptor-3 and related nucleic acids - useful to
 PT identify receptor inhibitors to treat inflammatory disease, e.g.
 PT autoimmune disorders, certain cancers, etc.
 XX
 XX Claim 10; Page 113-114; 153pp; English.
 XX
 CC A novel human receptor (AAW03377), designated Eos 12 or C-C chemokine
 CC receptor 3 (CCR-3), is involved in leukocyte migration associated
 CC with inflammation. Its sequence was deduced from a cDNA clone
 CC (AAW31335) isolated from a hyper-eosinophilic syndrome patient. A
 CC slightly different amino acid sequence (AAW03376) was deduced from a
 CC genomic clone (AAW31334) and a consensus sequence is given in AAW03378.
 CC Recombinant CCR-3 can be produced in host cells, and is useful for
 CC screening for CCR-3 ligands, promoters and inhibitors. The
 CC inhibitors can be used to treat inflammatory disease.
 CC
 XX Sequence 355 AA;
 SQ
 Query Match 100.0%; Score 1854; DB 17; Length 355;
 Best local Similarity 100.0%; Pred. No. 5.8e-201;
 Matches 355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 - QY 1 MTTSLDTVEFTGTSYYDDVGLCEKADTRALMAQVPPPLYSIVFTVGLGNVVMII 60
 Db 1 MTTSLDTVEFTGTSYYDDVGLCEKADTRALMAQVPPPLYSIVFTVGLGNVVMII 60
 QY 61 KTRRLKIMNTIYLNTAISDLFLVLPFPIHVHNGHNVFGHGKLLSGFYHTGLYSE 120
 Db 61 KTRRLKIMNTIYLNTAISDLFLVLPFPIHVHNGHNVFGHGKLLSGFYHTGLYSE 120
 QY 121 IFFIILLTDRLAIYHAFALRAATVTEGVTSIVTWGLAVLAALPEFIETEELFEE 180
 Db 121 IFFIILLTDRLAIYHAFALRAATVTEGVTSIVTWGLAVLAALPEFIETEELFEE 180
 QY 181 TICSALYPEDTVYSWRHFTLRMTIFCLVPLLVMAICYTGIIKTLRCPSSKKRYAIRL 240
 Db 181 TICSALYPEDTVYSWRHFTLRMTIFCLVPLLVMAICYTGIIKTLRCPSSKKRYAIRL 240
 QY 241 IFVIMAVFEIEMTPYVAVILSSYOSILGNCDESKHLDVMLVTEVAIYSHCCNPIY 300
 Db 241 IFVIMAVFEIEMTPYVAVILSSYOSILGNCDESKHLDVMLVTEVAIYSHCCNPIY 300
 QY 301 YAFVGERFRKYLHFFHRLMLHGLGRYIPFLPSEKLEKTSVSPSTAEPDELSTIVF 355
 Db 301 YAFVGERFRKYLHFFHRLMLHGLGRYIPFLPSEKLEKTSVSPSTAEPDELSTIVF 355
 RESULT 2
 AAW31850
 ID AAW31850 standard; Protein; 355 AA.
 XX
 AC AAW31850;
 XX
 DT 07-MAY-1998 (first entry)
 XX
 DE Human eosinophil eotaxin receptor protein CC CCR3.
 XX
 KW Eosinophil eotaxin receptor; CC CCR3; human; treatment; dermatitis;
 KW atopic condition; allergic rhinitis; conjunctivitis; bronchial asthma;
 KW beta-chemokine receptor; viral infection.
 XX
 OS Homo sapiens.
 XX
 PN W09741154-A1.
 XX
 PD 06-NOV-1997.
 XX

PF 24-APR-1997; 97MO-US06568.
 XX
 XX 17-JAN-1997; 97GB-0000894.
 PR 26-APR-1996; 96US-0016158.
 PR 26-APR-1996; 96US-0017113.
 XX
 PA (MERT) MERCK & CO INC.
 XX
 XX Daugherty BL, Demartino JA, Siciliano SJ, Springer MS;
 PI N-PSDB; AAW93601.
 DR WPI; 1997-549685/50.
 XX
 CC This is a human eosinophil eotaxin receptor. The 5099 base pair encoding
 CC cDNA sequence comprises a 1065 base pair open reading frame encoding this
 CC 355 amino acid eosinophil eotaxin receptor protein, flanked by a 5'
 CC genomic DNA sequence and a 3' terminator region. This novel eosinophil
 CC eotaxin receptor is a human beta-chemokine receptor designated CC CCR3.
 CC Agents which bind to this eosinophil eotaxin receptor can be used for
 CC the treatment and prevention of atopic conditions such as allergic
 CC rhinitis, dermatitis, conjunctivitis and bronchial asthma. Agents which
 CC block this eosinophil eotaxin receptor can be used to prevent viral
 CC infection in healthy individuals and slow or halt viral progression
 CC in infected patients.
 CC
 XX Sequence 355 AA;
 SQ
 Query Match 100.0%; Score 1854; DB 18; Length 355;
 Best local Similarity 100.0%; Pred. No. 5.8e-201;
 Matches 355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTTSLDTVEFTGTSYYDDVGLCEKADTRALMAQVPPPLYSIVFTVGLGNVVMII 60
 Db 1 MTTSLDTVEFTGTSYYDDVGLCEKADTRALMAQVPPPLYSIVFTVGLGNVVMII 60
 QY 61 KTRRLKIMNTIYLNTAISDLFLVLPFPIHVHNGHNVFGHGKLLSGFYHTGLYSE 120
 Db 61 KTRRLKIMNTIYLNTAISDLFLVLPFPIHVHNGHNVFGHGKLLSGFYHTGLYSE 120
 QY 121 IFFIILLTDRLAIYHAFALRAATVTEGVTSIVTWGLAVLAALPEFIETEELFEE 180
 Db 121 IFFIILLTDRLAIYHAFALRAATVTEGVTSIVTWGLAVLAALPEFIETEELFEE 180
 QY 181 TICSALYPEDTVYSWRHFTLRMTIFCLVPLLVMAICYTGIIKTLRCPSSKKRYAIRL 240
 Db 181 TICSALYPEDTVYSWRHFTLRMTIFCLVPLLVMAICYTGIIKTLRCPSSKKRYAIRL 240
 QY 241 IFVIMAVFEIEMTPYVAVILSSYOSILGNCDESKHLDVMLVTEVAIYSHCCNPIY 300
 Db 241 IFVIMAVFEIEMTPYVAVILSSYOSILGNCDESKHLDVMLVTEVAIYSHCCNPIY 300
 QY 301 YAFVGERFRKYLHFFHRLMLHGLGRYIPFLPSEKLEKTSVSPSTAEPDELSTIVF 355
 Db 301 YAFVGERFRKYLHFFHRLMLHGLGRYIPFLPSEKLEKTSVSPSTAEPDELSTIVF 355
 RESULT 3
 AAW27124
 ID AAW27124 standard; Protein; 355 AA.
 XX
 AC AAW27124;
 XX
 DT 14-DEC-1997 (first entry)
 XX
 DE Human chemokine receptor 88-2B.
 XX
 KW Chemokine receptor 88-2B; atherosclerosis; rheumatoid arthritis;
 KW

KW	tumour; asthma; viral infection; AIDS; inflammation;
RW	autoimmune disease; therapy; diagnosis; leukocyte trafficking;
KM	G protein coupled receptor; ligand; modulator; antibody; human.
XX	
OS	Homo sapiens.
XX	
FH	Key
FT	Domain
FT	/label- Extracellular_domain
FT	60..71
FT	/label- Intracellular_domain
FT	93..107
FT	Domain
FT	/label- Extracellular_domain
FT	131..151
FT	/label- Intracellular_domain
FT	171..196
FT	Domain
FT	/label- Extracellular_domain
FT	219..240
FT	Domain
FT	/label- Intracellular_domain
FT	263..284
FT	/label- Extracellular_domain
FT	306..335
FT	Domain
FT	/label- Intracellular_domain
XX	
PN	WO9722698-A2.
XX	
PD	26-JUN-1997.
XX	
PF	20-DEC-1996; 96WO-US20759.
XX	
PR	07-JUN-1996; 96US-0661393.
PR	20-DEC-1995; 95US-0575967.
XX	
PA	(ICOS-) ICOS CORP.
XX	
PI	Gray PW, Raport CJ, Schweickart VL;
XX	
DR	WPI; 1997-341689/31.
DR	N-PSDB; AAT85162.
XX	
PT	New nucleic acid encoding chemokine receptors 88-2B and 88C - used
PT	to modulate leukocyte trafficking; e.g. for treatment of
PT	Inflammation, tumours, viral infections, autoimmune diseases, etc.
XX	
PS	Claim 1; Page 50-51; 65pp; English.
XX	
CC	This polypeptide sequence comprises novel human chemokine receptor
CC	88-2B, a G protein coupled receptor that is involved in leukocyte
CC	trafficking. Its amino sequence was deduced from a cDNA clone
CC	(AA85162) isolated from a macrophage library. It shows 72% identity
CC	to CCR1. Chemokine receptor 88C (see AA87123) has also been
CC	identified. 88C and 88-2B receptors and their polypeptide fragments
CC	can be produced in transformed host cells. The receptors, peptides
CC	comprising one or more of the extracellular or intracellular
CC	domains, and anti-receptor antibodies can be used to modulate
CC	receptor activities, particularly ligand and G protein binding, and
CC	are potentially useful in the treatment of
CC	atherosclerosis, rheumatoid arthritis, tumours, asthma, viral
CC	infection, AIDS, inflammatory conditions, pathological immune
CC	response, abnormal haematopoietic processes etc.
XX	
SO	Sequence 355 AA;
Query Match	100.0%; Score 1854; DB 18; Length 355;
Best Local Similarity	100.0%; Pred. No. 5.8e-201;
Matches 355; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
OY	1 MTTSIDVETEGTSTSYDDVGILCEKAPTRALMAQFVPPLXSVFTVGLGNVVVMILI 60
Db	1 MTTSIDVETEGTSTSYDDVGILCEKAPTRALMAQFVPPLXSVFTVGLGNVVVMILI 60
OY	61 KYRRLRMFTNIIYLMLAISDLLEVTLPFWIHYVGNMWVGHGCKLLSGFYHTGLYSE 120

Db	61	KYRRLRMTNIIYLLNLAISDLEFLVTLPPWIIHYVGHMVPFGHCKKLLSGFIYHTGLYSE	120
Oy	121	IFEFILITLDYRLDAIVHAVALRARTVTEGVTISIVTGLAVLAALPEFIYETEELFEE	180
Db	121	IFEFILITLDYRLDAIVHAVALRARTVTEGVTISIVTGLAVLAALPEFIYETEELFEE	180
Oy	181	TLCGALYPEDTVYSMNHFFTLKMTIFCLVLPPLVNAICYTGIIKTLLRCPSKKRYKAIRL	240
Db	181	TLCGALYPEDTVYSMNHFFTLKMTIFCLVLPPLVNAICYTGIIKTLLRCPSKKRYKAIRL	240
Oy	241	IFVYMAVEFEMFPYVNAIILSSYOSILFGNDCERSKHLDVMLVTEVIAVSHCCMPVI	300
Db	241	IFVYMAVEFEMFPYVNAIILSSYOSILFGNDCERSKHLDVMLVTEVIAVSHCCMPVI	300
Oy	301	YAFVGENFRKYLHFFHFRHLLMHLGRYIFPLPSEKLEKRTSSVSPSTAPELSIYF	355
Db	301	YAFVGENFRKYLHFFHFRHLLMHLGRYIFPLPSEKLEKRTSSVSPSTAPELSIYF	355
RESULT 4			
ID	AAW51745	AAW51745 standard; Protein; 355 AA.	
XX	AAW51745;		
AC	AAW51745;		
XX	28-SEP-1998	(first entry)	
DT	28-SEP-1998	(first entry)	
XX	Human C-C chemokine receptor 3.		
DE	Human C-C chemokine receptor 3.		
XX	C-C chemokine receptor 3; CCR3; Eos L2; human;		
KM	G protein-coupled receptor; leukocyte; antibody; antagonist;		
KM	Inflammation; allergy; asthma; graft rejection; infection;		
KM	autoimmune disease; drug screening; therapy.		
XX			
OS	Homo sapiens.		
XX			
FH	Key	Location/Qualifiers	
FT	Misc-difference 24	/note- "conserved cysteine residue"	
FT	Misc-difference 106	/note- "conserved cysteine residue"	
FT	Misc-difference 183	/note- "conserved cysteine residue"	
FT	Misc-difference 273	/note- "conserved cysteine residue"	
FT	Peptide	/note- "conserved cysteine residue"	
FT	Modified-site	130..138	
FT	Modified-site	231	
FT	Modified-site	333	
FT	Modified-site	/note- "protein kinase C phosphorylation site"	
XX			
XX	W09814480-A1.		
XX			
PD	09-APR-1998.		
XX			
PF	24-SEP-1997;	97MO-USI7103.	
XX			
PR	30-SEP-1996;	96DS-0720565.	
XX			
PA	(LEUK-) LEUKOSITE INC.		
XX			
PI	Mackay CR, Ponath PD;		
XX			
DR	WPI; 1998-286418/25.		
DR	N-PSDB; AAV07403.		
XX			
PT	Antibodies to chemokine receptor-3 protein - useful for diagnosis		
PT	and treatment of inflammatory conditions, e.g. allergy, asthma,		
PT	autoimmune disease, graft rejection or cancer		
XX			
PS	Example 2; Page 136-137; 185pp; English.		
XX			


```

Db      |||
121 IFFIILLTIDRYLAIVHAFALRARVTFGVITSIVTWGLAVLAALPEFIYETEELFEE 180
Qy      181 TLCSALYPEDTVSMRPHHTLRMTIFCLVLPPLVMAICVYGIITKLRCPKRRKKAIRL 240
Db      181 TLCSALYPEDTVSMRPHHTLRMTIFCLVLPPLVMAICVYGIITKLRCPKRRKKAIRL 240
Qy      241 IFVIMAVFIFMTPEYNNVAILSSYOSILFGNDCRSKHLDMVLVTEVIASHCCMPVI 300
Db      241 IFVIMAVFIFMTPEYNNVAILSSYOSILFGNDCRSKHLDMVLVTEVIASHCCMPVI 300
Qy      301 YAFVGERFRKYLRRHFHRLMLHGRYIPPLPSEKLEKTSVSPSTAPELSIVF 355
Db      301 YAFVGERFRKYLRRHFHRLMLHGRYIPPLPSEKLEKTSVSPSTAPELSIVF 355

RESULT 6
AAE15320 standard; Protein; 355 AA.
AC      AAE15320;
XX      12-MAR-2002 (first entry)
DE      Human chemokine (C-C motif) receptor 3 (CCR3) protein.
XX      Human; chemokine (C-C motif) receptor 3; CCR3 gene; haplotyping;
KW      genotyping; type IV hypersensitivity reaction; HIV-1; gene therapy;
KW      human immunodeficiency virus 1; single nucleotide polymorphism; SNP;
KW      chromosome 3p21.3.
XX      Homo sapiens.
OS
XX      Key      Location/Qualifiers
FH      Misc-difference 351
FT      /note= "Ileu at this position is replaced with Pro
FT      due to single nucleotide polymorphism (SNP)".
XX      WO200187908-A2.
XX      22-NOV-2001.
XX      18-MAY-2001; 2001WO-US16278.
XX      18-MAY-2000; 2000US-205191P.
XX      (GENA-) GENAISSANCE PHARM INC.
XX      PA
XX      Chot JY, Kazemt A, Koshy B;
XX      WPI; 2002-055681/07.
XX      DR      N-PSDB; AAD25221, AAD25222.
XX      PT      Isolated polymorphic variants of chemokine (C-C motif) receptor 3
XX      (CCR3) gene useful for studying function of CCR3, expressing the CCR3
XX      protein and to screen drugs to treat CCR3 activity-related diseases -
XX      Claim 28; Fig 3; 53pp; English.
XX
XX      The invention relates to genetic variants of human chemokine (C-C motif)
XX      receptor 3 (CCR3) gene. The invention also relates to compositions and
XX      methods for haplotyping and/or genotyping the CCR3 gene in an individual.
XX      Polynucleotides of the invention are useful for studying the expression
XX      and function of CCR3 and in expressing CCR3 proteins for use in screening
XX      candidate drugs to treat diseases related to CCR3 activity. They are also
XX      used in gene therapy. The polymorphism and haplotype data is useful for
XX      validating whether CCR3 is a suitable target for drugs to treat type IV
XX      hypersensitivity reactions and human immunodeficiency virus (HIV)-1,
XX      screening for such drugs and reducing bias cells in clinical trials of
XX      such drugs. The genotyping method is useful for determining whether an
XX      individual has one haplotype or haplotype pairs. The haplotyping method
XX      is useful for improving the efficiency and outcome of several steps in
XX      the discovery and development of drugs for treating diseases associated

```

```

CC      with CCR3 activity such as type IV hypersensitivity reactions and HIV-1.
CC      The present sequence is human CCR3 protein. The CCR3 gene is located on
CC      chromosome 3p21.3.
XX      Sequence 355 AA;
Sx      Query Match      100.0%; Score 1854; DB 23; Length 355;
          Best Local Similarity 100.0%; Pred. No. 5,8e-201;
          Matches 355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 MTSIDVYETGRTSYDDVGLCEKADTRALMAQFPPLYSIVFTYGLGNVYVAILI 60
Db      1 MTSIDVYETGRTSYDDVGLCEKADTRALMAQFPPLYSIVFTYGLGNVYVAILI 60
Qy      61 KYRRLRITNTIYLNALISDLFLVTLPEFVHYRGHWVYRGHCKLLSGFYHTGLXSE 120
Db      61 KYRRLRITNTIYLNALISDLFLVTLPEFVHYRGHWVYRGHCKLLSGFYHTGLXSE 120
Qy      121 IFFIILLTIDRYLAIVHAFALRARVTFGVITSIVTWGLAVLAALPEFIYETEELFEE 180
Db      121 IFFIILLTIDRYLAIVHAFALRARVTFGVITSIVTWGLAVLAALPEFIYETEELFEE 180
Qy      181 TLCSALYPEDTVSMRPHHTLRMTIFCLVLPPLVMAICVYGIITKLRCPKRRKKAIRL 240
Db      181 TLCSALYPEDTVSMRPHHTLRMTIFCLVLPPLVMAICVYGIITKLRCPKRRKKAIRL 240
Qy      241 IFVIMAVFIFMTPEYNNVAILSSYOSILFGNDCRSKHLDMVLVTEVIASHCCMPVI 300
Db      241 IFVIMAVFIFMTPEYNNVAILSSYOSILFGNDCRSKHLDMVLVTEVIASHCCMPVI 300
Qy      301 YAFVGERFRKYLRRHFHRLMLHGRYIPPLPSEKLEKTSVSPSTAPELSIVF 355
Db      301 YAFVGERFRKYLRRHFHRLMLHGRYIPPLPSEKLEKTSVSPSTAPELSIVF 355

RESULT 7
AAW03376 standard; Protein; 355 AA.
ID      AAW03376;
XX      AAW03376;
XX      15-NOV-1996 (first entry)
DE      CC-chemokine receptor 3.
XX      CC-chemokine receptor 3.
XX      Human; chemokine receptor 3; CRP-3; Bos-L2; inhibitor; antisense;
XX      antiinflammatory; eosinophil.
XX      Homo sapiens.
OS
XX      Key      Location/Qualifiers
FH      Region      130..138
FT      /note= "amino acids 130-138 comprise a motif
FT      conserved among C-X-C and C-C chemokine
FT      receptors".
XX      WO9622371-A2.
XX      25-JUL-1996.
XX      19-JAN-1996; 96WO-US00608.
XX      19-JAN-1995; 95US-0375199.
XX      (BGM) BRIGHAM & WOMENS HOSPITAL.
XX      (CHIL-) CHILDRENS MEDICAL CENT.
XX      (LEBK-) LEUKOSITE INC.
XX      Gerard CJ, Gerard NP, Mackay CR, Ponath PD, Post TW;
XX      Qin S;
XX      WPI; 1996-354528/35.
XX      DR      N-PSDB; AAT31334.

```

XX Mammalian chemokine receptor-3 and related nucleic acids - useful to
PT identify receptor inhibitors to treat inflammatory disease, e.g.
PT autoimmune disorders, certain cancers, etc.
PS Claim 10; Page 110-111; 153pp; English.
XX
XX
CC A novel human receptor (AAW03376), designated Bos L2 or C-C chemokine
CC receptor 3 (CCR-3), is involved in leukocyte migration associated
CC with inflammation. Its sequence was deduced from a genomic DNA
CC clone (AA1334). A slightly different amino acid sequence (AAW03377)
CC was deduced from a cDNA clone (AA1335) and a consensus sequence
CC is given in AAW03378. Recombinant CCR-3 can be produced in host
CC cells, and is useful for screening for CCR-3 ligands, promoters
CC and inhibitors. The inhibitors can be used to treat inflammatory
CC disease.
XX
XX
SQ Sequence 355 AA:

Query Match 99.8%; Score 1851; DB 17; Length 355;
Best Local Similarity 99.7%; Pred. No. 1.3e-200;
Matches 354; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

=OY 1 MTTSLDTVEFGTSTYDDVGLCEKADRALMAOPFPLYSIVFTVGLGNVVMII 60
DB 1 MTTSLDTVEFGTSTYDDVGLCEKADRALMAOPFPLYSIVFTVGLGNVVMII 60
OY 61 KYRRLIMTNIYILNLAISDLFLVYLPMIHVYRGNHNVFGHCKLISGFTHTLASE 120
DB 61 KYRRLIMTNIYILNLAISDLFLVYLPMIHVYRGNHNVFGHCKLISGFTHTLASE 120
OY 121 IFFIILLTDRILAYANFAARARVTVGVTSITVWGLAVYALPERIFETELFEE 180
DB 121 IFFIILLTDRILAYANFAARARVTVGVTSITVWGLAVYALPERIFETELFEE 180
OY 181 TLCSALYPRDYVSMRHFHTLMTIFCLVPLLVMAICTGIIKTLRPSKKRYAIRL 240
DB 181 TLCSALYPRDYVSMRHFHTLMTIFCLVPLLVMAICTGIIKTLRPSKKRYAIRL 240
OY 241 IFVIAVFEFTFPYVAVAILSSYOSILFNCDESKHLDVMTVETVIAVSHCCNPYI 300
DB 241 IFVIAVFEFTFPYVAVAILSSYOSILFNCDESKHLDVMTVETVIAVSHCCNPYI 300
OY 301 YAFVGRFRKYLRRHFRHLIMHIGRYTFLPSEKLETSVSPSTAEPELSIVF 355
DB 301 YAFVGRFRKYLRRHFRHLIMHIGRYTFLPSEKLETSVSPSTAEPELSIVF 355

RESULT 8
AAW10100
ID AAW10100 standard; Protein; 355 AA.
XX
XX AAW10100;
XX
XX 30-SEP-1997 (first entry)
XX
XX Human C-C chemokine receptor 3.
XX
XX Human; ectaxin; eosinophil; chemoattractant; stimulation;
XX accumulation; attraction; chemotaxis; diagnosis; prevention;
XX treatment; disease; inflammation; allergy; asthma; rhinitis;
XX hypersensitivity; lung; pneumonia; Loeffler's; syndrome;
XX interstitial; ILD; idiopathic pulmonary fibrosis;
XX rheumatoid arthritis; systemic; lupus erythematosus; SLE;
XX ankylosing spondylitis; scleritis; Sjogren's; polymyositis;
XX dermatomyositis; bowel; anaphylaxis; drug; penicillin;
XX cephalosporin; insect sting; Crohn's; ulcerative colitis;
XX spondyloarthropathy; scleroderma; psoriasis; dermatosis;
XX dermatitis; eczema; atopic; urticaria; neuroticism; cutaneous;
XX vasculitis; myositis; fascitis; multiple sclerosis;
XX myasthenia gravis; juvenile onset diabetes; glomerulonephritis;
XX autoimmune; thyroiditis; Bechet's; graft; rejection;
XX transplantation; allograft; graft versus host; cancer;

KW leukocyte infiltration; reperfusion injury; atherosclerosis;
KW haematologic malignancy; septic; endotoxic; shock;
KW polymyositis; dermatomyositis; immunosuppression; immunodeficiency;
KW AIDS; radiation therapy; chemotherapy; autoimmune; corticosteroid;
KW C-C chemokine receptor 3; CCR3.
XX
XX
OS Homo sapiens.
XX
XX WO9700960-A1.
XX
XX 09-JAN-1997.
XX
XX 21-JUN-1996; 96WO-0510723.
XX
XX 23-JUN-1995; 95US-0494093.
XX
XX (LEUK-) LEUKOSITE INC.
XX
XX Mackay C, Newman W, Ponath PD, Qin S, Ringler DJ;
XX MPI: 1997-087387/08.
XX DR N-PSDB; AAT58783.
XX
XX New isolated human ectaxin gene - used to develop prods. for the
XX diagnosis and treatment of e.g. inflammation, allergies, auto-immune
XX disease, infections and tumours
XX
XX Example 7; Pages 98-99; 130pp; English.
XX
XX The present sequence is human C-C chemokine receptor 3 (CCR3),
XX to which human ectaxin (hE), an eosinophil specific chemoattractant
XX capable of stimulating eosinophil accumulation and/or attracting
XX eosinophils (including chemotaxis), binds.
XX he can be used to develop products for the diagnosis, prevention or
XX treatment of the associated diseases or conditions. The products can
XX be used to treat inflammatory or allergic diseases and conditions,
XX including respiratory allergic diseases (e.g. asthma, allergic
XX rhinitis, hypersensitivity lung diseases or pneumonitis,
XX eosinophilic pneumonias such as Loeffler's syndrome and chronic
XX eosinophilic pneumonia, interstitial lung diseases (ILD) such as
XX idiopathic pulmonary fibrosis or IIP associated with rheumatoid
XX arthritis, systemic lupus erythematosus (SLE), ankylosing
XX spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis
XX or dermatomyositis), systemic anaphylaxis or hypersensitivity
XX responses, drug allergies (e.g. to penicillin and cephalosporins),
XX insect sting allergies, inflammatory bowel diseases (e.g. Crohn's
XX disease and ulcerative colitis), spondyloarthropathies,
XX scleroderma, psoriasis and inflammatory dermatoses (e.g.
XX dermatitis, eczema, atopic dermatitis, allergic contact dermatitis,
XX urticaria and necrotizing, cutaneous and hypersensitivity
XX vasculitis), eosinophilic myositis and fascitis, multiple
XX sclerosis, SLE, myasthenia gravis, juvenile onset diabetes,
XX glomerulonephritis, autoimmune thyroiditis, Bechet's disease, graft
XX rejection (e.g. in transplantation) including allograft rejection or
XX graft versus host disease and cancers with leukocyte infiltration
XX of the skin or organs. The products can also be used to treat other
XX diseases or conditions requiring the inhibition of undesirable
XX inflammatory responses, including reperfusion injury,
XX atherosclerosis, certain haematologic malignancies, cytokine
XX induced toxicity (e.g. septic or endotoxic shock), polymyositis,
XX dermatomyositis, immunosuppression (e.g. in individuals with
XX immunodeficiency syndromes such as AIDS, undergoing radiation
XX therapy, chemotherapy, therapy for autoimmune disease or other drug
XX therapy, such as corticosteroid therapy, which causes
XX immunosuppression), immunosuppression due to (e.g. congenital)
XX deficiency (e.g. in ectaxin) or infectious diseases such as parasitic
XX diseases.
XX Degenerate primers based on the guinea pig ectaxin amino acid
XX sequence were used for the reverse transcriptase polymerase chain
XX reaction (RT-PCR) amplification of RNA isolated from inflamed,
XX eosinophilic lung tissue obtained from Balb/c mice sensitised to
XX ovalbumin. The amplification product was used as a probe to screen
XX a human genomic library in vector EMB3 SP6/77 to obtain the hE

CC gene.
 XX Sequence 355 AA;
 S0
 Query Match 99.8%; Score 1851; DB 18; Length 355;
 Best Local Similarity 99.7%; Pred. No. 1.3e-200;
 Matches 354; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTSIDIVETFGTTSYDDVGLCEKADTRALMAQFVPLSLVFTVGLGNVVMILI 60
 DB 1 MTSIDIVETFGTTSYDDVGLCEKADTRALMAQFVPLSLVFTVGLGNVVMILI 60
 QY 61 KYRLRLMTNTIYLNLAISDLLFLVTLPEFWIHYVGNHNVGHGCKLLSGFYHTGLYSE 120
 DB 61 KYRLRLMTNTIYLNLAISDLLFLVTLPEFWIHYVGNHNVGHGCKLLSGFYHTGLYSE 120
 QY 121 IFFIILITIDRYLAIHVAFPALRARTVFGVITSLVWGVLVLAALPEFIYTEELPEE 180
 DB 121 IFFIILITIDRYLAIHVAFPALRARTVFGVITSLVWGVLVLAALPEFIYTEELPEE 180
 QY 181 TLCALYPEDTVYSNRHFTLRMTIFCLVPLVLAICVGTGIIKTLNCPKRYKAI 240
 DB 181 TLCALYPEDTVYSNRHFTLRMTIFCLVPLVLAICVGTGIIKTLNCPKRYKAI 240
 QY 241 IFVIMAVFIFWTPYNNVAIILSSYOSILFGNDCERSKLDLVMVTEVIAYSHCCMPVI 300
 DB 241 IFVIMAVFIFWTPYNNVAIILSSYOSILFGNDCERSKLDLVMVTEVIAYSHCCMPVI 300
 QY 301 YAFGERFRKYLRFHFRHLMLHGRYIPFLPSEKLENTSSVSPSTAPELSIYF 355
 DB 301 YAFGERFRKYLRFHFRHLMLHGRYIPFLPSEKLENTSSVSPSTAPELSIYF 355

RESULT 9
 ABB07733
 ID ABB07733 standard; Protein: 355 AA.
 AC ABB07733;
 DT 10-JUN-2002 (first entry)
 XX
 DE Human C-C chemokine receptor 3 (CCR3) protein.
 XX
 KW Mucosae-associated epithelial chemokine; MEC; C-C chemokine receptor;
 KW CCR3; CCR10; anti-inflammatory; cytostatic; immunomodulator; anti-viral;
 KW antibacterial; chemokine; human.
 XX
 OS Homo sapiens.
 XX
 FN WO200214532-A2.
 XX
 PD 21-FEB-2002.
 XX
 PE 15-AUG-2001; 2001MO-US25734.
 XX
 PR 15-AUG-2000; 2000US-0638914.
 XX
 PA (MIL-) MILLENNIUM PHARM INC.
 PA (SPRD) UNIV LELAND STANFORD JUNIOR.
 XX
 PI Butcher EC, Kunkel EJ, Pan J, Soler-Ferran D;
 XX
 DR WPI; 2002-269204/31.
 DR N-PSDB; ABL40462.
 XX
 XX Identifying modulators of mucosae-associated epithelial chemokine (MEC)
 PT receptors 3 or 10 (CCR3/10), useful for treating inflammatory diseases,
 PT comprises detecting formation of MEC-CCR3/10 complex or modulation of a
 PT MEC-induced response -
 XX
 PS Example 2; Fig 5; 92pp; English.
 XX
 CC The invention relates to identifying agents that inhibit or promote the

CC binding of a mammalian mucosae-associated epithelial chemokine (MEC) to
 CC a mammalian C-C chemokine receptor 3 (CCR3) or 10 (CCR10). The method
 CC involves: (a) detecting or measuring the formation of a complex between
 CC the MEC, and the CCR3 or CCR10; or (b) determining the ability of the
 CC test agent to inhibit or augment a MEC-induced response. An augmentation
 CC of complex formation, relative to a control, is indicative that the agent
 CC is a promoter. The method is useful for identifying modulators (e.g.
 CC inhibitors or promoters) of MEC-induced functions of CCR3 and/or CCR10.
 CC The inhibitors are useful for treating inflammatory diseases or
 CC conditions in a subject, e.g. oral inflammatory condition (e.g. Sjogren's
 CC syndrome or Behcet's syndrome), mastitis, chronic obstructive lung
 CC disease, asthma, inflammatory bowel disease (e.g. Crohn's disease,
 CC ulcerative colitis or celiac disease), Iga nephropathy or dermatitis
 CC herpetiformis. The promoters are useful for treating cancers (e.g. solid
 CC tumours or cutaneous T cell lymphoma), neoplastic disease, retinopathy,
 CC macular degeneration, bacterial infections, tuberculous leprosy, viral
 CC infections, AIDS, neutropenias or bronchiectasis. The present sequence
 CC represents the human CCR3 protein.
 XX

S0 Sequence 355 AA;
 Query Match 99.8%; Score 1851; DB 23; Length 355;
 Best Local Similarity 99.7%; Pred. No. 1.3e-200;
 Matches 354; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTSIDIVETFGTTSYDDVGLCEKADTRALMAQFVPLSLVFTVGLGNVVMILI 60
 DB 1 MTSIDIVETFGTTSYDDVGLCEKADTRALMAQFVPLSLVFTVGLGNVVMILI 60
 QY 61 KYRLRLMTNTIYLNLAISDLLFLVTLPEFWIHYVGNHNVGHGCKLLSGFYHTGLYSE 120
 DB 61 KYRLRLMTNTIYLNLAISDLLFLVTLPEFWIHYVGNHNVGHGCKLLSGFYHTGLYSE 120
 QY 121 IFFIILITIDRYLAIHVAFPALRARTVFGVITSLVWGVLVLAALPEFIYTEELPEE 180
 DB 121 IFFIILITIDRYLAIHVAFPALRARTVFGVITSLVWGVLVLAALPEFIYTEELPEE 180
 QY 181 TLCALYPEDTVYSNRHFTLRMTIFCLVPLVLAICVGTGIIKTLNCPKRYKAI 240
 DB 181 TLCALYPEDTVYSNRHFTLRMTIFCLVPLVLAICVGTGIIKTLNCPKRYKAI 240
 QY 241 IFVIMAVFIFWTPYNNVAIILSSYOSILFGNDCERSKLDLVMVTEVIAYSHCCMPVI 300
 DB 241 IFVIMAVFIFWTPYNNVAIILSSYOSILFGNDCERSKLDLVMVTEVIAYSHCCMPVI 300
 QY 301 YAFGERFRKYLRFHFRHLMLHGRYIPFLPSEKLENTSSVSPSTAPELSIYF 355
 DB 301 YAFGERFRKYLRFHFRHLMLHGRYIPFLPSEKLENTSSVSPSTAPELSIYF 355

RESULT 10
 ABB07240
 ID ABB07240 standard; Protein: 355 AA.
 AC ABB07240;
 DT 26-MAR-2002 (first entry)
 XX
 DE Human CC chemokine receptor 3 (CCR3).
 XX
 KW CC chemokine receptor-3; CCR3; anti-allergic; anti-inflammatory; human;
 KW antiasthmatic; ophthalmological; dermatological; immunosuppressive;
 KW antipruritic.
 XX
 OS Homo sapiens.
 XX
 FN
 XX
 DE
 XX
 DE
 XX
 XX Key Location/Qualifiers
 FH 327..330
 FT Peptide /note="internalisation site; the modified CCR3 receptor
 FT /note="internalisation site; the modified CCR3 receptor
 FT FT comprises a deletion or mutation of the
 FT internalisation site"
 FT Region 333..353
 FT /note="the modified CCR3 receptor comprises a deletion

or mutation of at least one phosphorylation site
selected from positions 333, 339, 340, 341, 343,
346 and 353*

W0200192520-A1.

06-DEC-2001.

31-MAY-2001; 2001WO-EP06195.

01-JUN-2000; 2000GB-0013345.

(GLAX) GLAXO GROUP LTD.

Barnes AA, Fraser NJ, O'Shaughnessy CT, Wise A;

WPI; 2002-114347/15.

N-PSDB; ABA94340.

Modified CC chemokine receptor-3 useful for identifying modulators of
eotaxin-mediated CCR3 receptor for treating allergic and inflammatory
disorders, comprises modifications to stabilize or enhance surface
expression

Claim 1; Page 24-25; 29pp; English.

The invention relates to a CC chemokine receptor-3 (CCR3) modified to
stabilize or enhance expression of the receptor in a cell membrane.
Assays for investigating properties of the CCR3 receptor are useful for
the identification of modulators of eotaxin-mediated CCR3 receptor
activity. The identified modulators are useful in the treatment of
prophylaxis of allergic or inflammatory disorders which are responsive to
regulation of CCR3 receptor activity. The agents are also useful in the
treatment of allergy or asthma as well as ophthalmological, inflammatory,
gastrointestinal, dermatological, respiratory or pruritic disorders. The
agents are useful for treating conjunctivitis, inflammatory bowel disease,
eczema, allergic rhinitis, nasal polyposis, atopic dermatitis and
pruritis, chronic obstructive pulmonary disease (COPD) and other lung
disorders and immune disease. The present sequence represents the human
CCR3 receptor.

SQ Sequence 355 AA;

Query Match 99.8%; Score 1851; DB 23; Length 355;

Best Local Similarity 99.7%; Pred. No. 1.3e-200;

Matches 354; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTTSLDVTVEFGTSTSYDDVGLLCEKADTRALMAQFVPPYSLVFTVGLGNVVMILI 60

Db 1 MTTSLDVTVEFGTSTSYDDVGLLCEKADTRALMAQFVPPYSLVFTVGLGNVVMILI 60

QY 61 KRRRLRIMNTIYLNLAIISDLFLVTLPPWIIHYVGNHNVFGHGMCKLLSGFYHGLYSE 120

Db 61 KRRRLRIMNTIYLNLAIISDLFLVTLPPWIIHYVGNHNVFGHGMCKLLSGFYHGLYSE 120

QY 121 IFFIILLTDRILAIYHAFALRARTVGTSTSYTWGLAVIALPERIFETEELPEE 180

Db 121 IFFIILLTDRILAIYHAFALRARTVGTSTSYTWGLAVIALPERIFETEELPEE 180

QY 181 TICSALYPEDYVYWRNHFHTLMTIFCLVPLPLVNAICTGTGIKTLRCPSSKKYKARL 240

Db 181 TICSALYPEDYVYWRNHFHTLMTIFCLVPLPLVNAICTGTGIKTLRCPSSKKYKARL 240

QY 241 IFVIMAVFEIFTWTPYNAVALISSYOSILFGNDCERSKHLDLVNLVTEVLAISHCCMPYI 300

Db 241 IFVIMAVFEIFTWTPYNAVALISSYOSILFGNDCERSKHLDLVNLVTEVLAISHCCMPYI 300

QY 301 YAFVGERFRKYLRRHFHRLMLHGLRYIPFLPSEKLERSSVSPSTAEPELSIVF 355

Db 301 YAFVGERFRKYLRRHFHRLMLHGLRYIPFLPSEKLERSSVSPSTAEPELSIVF 355

RESULT 11

ABB56341

ID ABB56341 standard; Protein; 355 AA.

XX ABB56341;

DT 18-FEB-2002 (first entry)

DE Non-endogenous human GPCR protein, SEQ ID NO: 475.

KW Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;

KM constitutively activated GPCR; agonist; disease.

OS Homo sapiens.

PN Synthetic.

WO200177172-A2.

PD 18-OCT-2001.

PF 05-APR-2001; 2001WO-US11098.

PR 07-APR-2000; 2000US-195747P.

PA (AREN-) ARENA PHARM INC.

PI Lehmann-Bruinsma K, Liaw CW, Lin I;

DR WPI; 2001-648759/74.

N-PSDB; ABI97977.

PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
disease treatment, comprises contacting candidate compounds with

versions of GPCRs -

PS Claim 1; Page 276-277; 394pp; English.

The invention relates to G protein-coupled receptors (GPCRs) for which
the endogenous ligand has been identified. Non-endogenous
constitutively activated versions of known GPCRs are used in the
invention for the direct identification of candidate compounds as
receptor agonists, inverse agonists or partial agonists. Such
agonists are useful as therapeutic agents for diseases or disorders
associated with GPCRs. The present sequence is a non-endogenous
version of a known human GPCR.

SQ Sequence 355 AA;

Query Match 99.6%; Score 1847; DB 22; Length 355;

Best Local Similarity 99.7%; Pred. No. 3.6e-200;

Matches 354; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MTTSLDVTVEFGTSTSYDDVGLLCEKADTRALMAQFVPPYSLVFTVGLGNVVMILI 60

Db 1 MTTSLDVTVEFGTSTSYDDVGLLCEKADTRALMAQFVPPYSLVFTVGLGNVVMILI 60

QY 61 KRRRLRIMNTIYLNLAIISDLFLVTLPPWIIHYVGNHNVFGHGMCKLLSGFYHGLYSE 120

Db 61 KRRRLRIMNTIYLNLAIISDLFLVTLPPWIIHYVGNHNVFGHGMCKLLSGFYHGLYSE 120

QY 121 IFFIILLTDRILAIYHAFALRARTVGTSTSYTWGLAVIALPERIFETEELPEE 180

Db 121 IFFIILLTDRILAIYHAFALRARTVGTSTSYTWGLAVIALPERIFETEELPEE 180

QY 181 TICSALYPEDYVYWRNHFHTLMTIFCLVPLPLVNAICTGTGIKTLRCPSSKKYKARL 240

Db 181 TICSALYPEDYVYWRNHFHTLMTIFCLVPLPLVNAICTGTGIKTLRCPSSKKYKARL 240

QY 241 IFVIMAVFEIFTWTPYNAVALISSYOSILFGNDCERSKHLDLVNLVTEVLAISHCCMPYI 300

Db 241 IFVIMAVFEIFTWTPYNAVALISSYOSILFGNDCERSKHLDLVNLVTEVLAISHCCMPYI 300

QY 301 YAFVGERFRKYLRRHFHRLMLHGLRYIPFLPSEKLERSSVSPSTAEPELSIVF 355

Db 301 YAFVGERFRKYLRRHFHRLMLHGLRYIPFLPSEKLERSSVSPSTAEPELSIVF 355

DB 301 YAFVGERFRKYLRRHFFHRLMLHLCGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355

RESULT 12
AAW51744
ID AAW51744 standard; Protein; 355 AA.

XX
XX AAW51744;
XX
XX 28-SEP-1998 (first entry)
XX
XX Human C-C chemokine receptor 3.
XX
XX C-C chemokine receptor 3; CCR3; Bos L2; human;
XX G protein-coupled receptor; leukocyte; antibody; antagonist;
XX inflammation; allergy; asthma; graft rejection; infection;
XX autoimmune disease; drug screening; therapy.
XX
XX Homo sapiens.
XX
XX
XX Key Location/Qualifiers
XX
XX Misc-difference 24 /note= "conserved cysteine residue"
XX
XX Misc-difference 106 /note= "conserved cysteine residue"
XX
XX Misc-difference 183 /note= "conserved cysteine residue"
XX
XX Misc-difference 273 /note= "conserved cysteine residue"
XX
XX Peptide 130..138 /note= "C-C chemokine receptor conserved motif"
XX
XX Modified-site 231 /note= "protein kinase C phosphorylation site"
XX
XX Modified-site 333 /note= "protein kinase C phosphorylation site"
XX
XX W09814480-A1.
XX
XX 09-APR-1998.
XX
XX 24-SEP-1997; 97WO-US17103.
XX
XX 30-SEP-1996; 96US-0720565.
XX
XX (LEUK-) LEUKOSITE INC.
XX
XX Mackay CR, Ponath PD;
XX
XX MPI: 1998-286418/25.
XX
XX N-PSDB; AAV07402.
XX
XX Antibodies to chemokine receptor-3 protein - useful for diagnosis
XX
XX and treatment of inflammatory conditions, e.g. allergy, asthma,
XX
XX autoimmune disease, graft rejection or cancer
XX
XX
XX Example 2; Fig 1A-C; 185pp; English.
XX
XX
XX This polypeptide comprises novel human C-C chemokine receptor 3,
XX
XX also designated CCR-3, CCR3 or Bos L2, that binds and mediates
XX
XX chemotaxis in response to chemokines such as eotaxin, RANTES and
XX
XX MCP-3. Its amino acid sequence was deduced from an isolated
XX
XX genomic DNA sequence (see AAV07402). It differs slightly from the
XX
XX sequence (see AAW51745) deduced from a cDNA clone (see AAV07403); a
XX
XX consensus sequence for CCR-3 is provided (see AAW51746). The
XX
XX invention relates to isolated and/or recombinant nucleic acids
XX
XX encoding CCR-3, isolated or recombinant CCR-3 polypeptides,
XX
XX recombinant nucleic acid constructs, host cells useful for
XX
XX production of recombinant CCR-3 proteins, to antibodies reactive
XX
XX with the receptors, and to methods of using these products to
XX
XX identify ligands, antagonists and agonists of receptor function.
XX
XX Inhibitors of CCR-3 can be used to treat: inflammatory or allergic
XX
XX diseases and conditions, including respiratory allergic diseases
XX
XX such as asthma, allergic rhinitis, hypersensitivity lung disease,

hyperresponsivity pneumonitis, eosinophilic pneumonia (e.g.
Loeffler's syndrome, chronic eosinophilic pneumonia, interstitial
lung disease (ILD) e.g. idiopathic pulmonary fibrosis or ILD
associated with rheumatoid arthritis, systemic lupus erythematosus,
ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome,
polymyositis or dermatomyositis), systemic anaphylaxis or
hyperresponsivity responses, drug allergy, insect sting allergy,
inflammatory bowel disease, such as Crohn's disease and ulcerative
colitis, spondyloarthritis, scleroderma, psoriasis, inflammatory
dermatosis such as dermatitis, eczema, atopic dermatitis,
allergic contact dermatitis, urticaria, vasculitis (e.g. necrotizing,
cutaneous and hypersensitivity vasculitis); eosinophilic myositis
and eosinophilic fasciitis; autoimmune diseases such as rheumatoid
arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus
erythematosus, myasthenia gravis, juvenile onset diabetes,
glomerulonephritis, autoimmune thyroiditis and Behcet's disease;
CC graft rejection, including allograft rejection or graft-versus-host
disease; cancers with leukocyte infiltration of the skin or organs;
CC and also reperfusion injury, atherosclerosis, certain haematologic
CC malignancies, septic shock and endotoxic shock. Promoters of CCR-3
CC function can be used for treating: immunosuppression e.g. in AIDS
CC patients or individuals undergoing radiation therapy, chemotherapy,
CC therapy for autoimmune disease or other drug therapy, and
CC immunosuppression due to congenital deficiency in receptor function or
CC other causes; and infectious diseases such as parasitic diseases,
CC including helminth infections, such as nematodes (round worms).
CC The agents can also be used for detection and diagnosis.

Sequence 355 AA:

Query Match 99.6%; Score 1846; DB 19; Length 355;
Best Local Similarity 99.4%; Pred. No. 4,7e-200;
Matches 353; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 MTTSDPYETRECTGYDVGILCKAPTRALMAQFVPLSLVTVGLGVVVMILI 60
DB 1 MTTSDPYETRECTGYDVGILCKAPTRALMAQFVPLSLVTVGLGVVVMILI 60
QY 61 KYRRLRIMNTIYLMLAISDLLFLVLPFWIHVYGVHVMVFGHGKCKLLSGFYHTGLYSE 120
DB 61 KYRRLRIMNTIYLMLAISDLLFLVLPFWIHVYGVHVMVFGHGKCKLLSGFYHTGLYSE 120
QY 121 IFFILLTIDRLAVHAVFARARVTVGVITSTVTVGLAVLALPFIPIETELLEE 180
DB 121 IFFILLTIDRLAVHAVFARARVTVGVITSTVTVGLAVLALPFIPIETELLEE 180
QY 181 TICSALYPEDFYVSRHFHTLMTIFCYLPLLVNAICYTGIIKTLCPSSKKKRAIRL 240
DB 181 TICSALYPEDFYVSRHFHTLMTIFCYLPLLVNAICYTGIIKTLCPSSKKKRAIRL 240
QY 241 IFVNAVFEIFWTPYVNAIILSSYOSILFGNDCERSKHLDLVMTVEYIANSHCMPVI 300
DB 241 IFVNAVFEIFWTPYVNAIILSSYOSILFGNDCERSKHLDLVMTVEYIANSHCMPVI 300
QY 301 YAFVGERFRKYLRRHFFHRLMLHLCGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
DB 301 YAFVGERFRKYLRRHFFHRLMLHLCGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355

RESULT 13
AAW25943
ID AAW25943 standard; Protein; 356 AA.

XX
XX AAW25943;
XX
XX 13-MAR-1998 (first entry)
XX
XX Human CCR3 chemokine receptor.
XX
XX CCR3 chemokine; mouse; primer; PCR; amplification; antagonist; human;
XX
XX abnormal physiology; development; anti-viral; probe; hybridisation.
XX
XX Homo sapiens.

XX MO9721812-A2.
 XX 19-JUN-1997.
 XX 05-DEC-1996; 96MO-US19139.
 XX 08-DEC-1995; 95US-0567882.
 XX (SCHE) SCHERING CORP.
 XX Daiyaghi DJ, Hara T, Miyajima A, Schall TJ, Wang W;
 XX Yoshimura A;
 XX WPI; 1997-332784/30.
 XX N-PSDB; AAT79096.
 XX
 XX New isolated chemokine CCR8 and chemokine receptor CCR3 - used to
 XX develop products useful for the diagnosis and treatment of
 XX conditions associated with abnormal physiology or development
 XX
 XX Claim 15; Page 60-62; 73pp; English.
 XX
 XX This is the amino acid sequence of a novel CCR3 chemokine receptor
 XX isolated from a T10-activated human T-cell cDNA library using the
 XX sequence amplified by primers AAT79097 and AAT79098 as a probe.
 XX The encoded protein can be used to screen for (ant)agonists that bind
 XX to the novel CCR8 chemokines (AAW25941 and AAW25942). These
 XX (ant)agonists are useful in the treatment of conditions associated with
 XX abnormal physiology or development.
 XX
 XX Sequence 356 AA;
 SO
 Query Match 98.5%; Score 1826.5; DB 18; Length 356;
 Best Local Similarity 98.6%; Pred. No. 7.6e-198;
 Matches 351; Conservative 2; Mismatches 2; Indels 1; Gaps 1;
 QY 1 MTSLDTVEFTGTTSTYDDVGLCEKADRALMAQFVPPPLYSLVFTVGLGNVVMYI 60
 DB 1 MTSLDTVEFTGTTSTYDDVGLCEKADRALMAQFVPPPLYSLVFTVGLGNVVMYI 60
 QY 61 KYRRLRIMNTIYLNLAIISDLFLVTLPMIHYVRGNVFGHGCKLLSGFYHTGLYSE 120
 DB 61 KYRRLRIMNTIYLNLAIISDLFLVTLPMIHYVRGNVFGHGCKLLSGFYHTGLYSE 120
 QY 121 IFFIILLTDRYLAIVHAVALPARKVTVGVTSITWGLAVLAALPEFIYETEELFEE 180
 DB 121 IFFIILLTDRYLAIVHAVALPARKVTVGVTSITWGLAVLAALPEFIYETEELFEE 180
 QY 181 TICSALYPEDTVYSMRHFTLRMTICLVLPILVMAICYGTIITLLRCPSSKKRYAIRL 240
 DB 181 TICSALYPEDTVYSMRHFTLRMTICLVLPILVMAICYGTIITLLRCPSSKKRYAIRL 240
 QY 241 IFVIMAVFIFMTPTVNAVALILSSYOSILFGNDCERSKHLDMVLTVEVLAISH-COMNPY 299
 DB 241 IFVIMAVFIFMTPTVNAVALILSSYOSILFGNDCERSKHLDMVLTVEVLAISH-COMNPY 299
 QY 300 IYAFVGERFRKYLHFFHRHLLMHLGRYIPFLPSEKLEKTSVSPSTAEPBELSIVF 355
 DB 301 IYAFVGERFRKYLHFFHRHLLMHLGRYIPFLPSEKLEKTSVSPSTAEPBELSIVF 355
 RESULT 14
 AAW03378
 ID AAW03378 standard; Protein; 355 AA.
 XX AAW03378;
 AC AAW03378;
 DT 15-NOV-1996 (first entry)
 XX
 XX CC-chemokine receptor 3 consensus sequence.
 DE CC-chemokine receptor 3; CRP-3; Eos-L2; Inhibitor; antisense;
 KW

KW antiinflammatory; eosinophil.
 XX Homo sapiens.
 OS
 XX
 XX Key Location/Qualifiers
 FH Misc-difference 276 /Label= Thr, Ser
 FT
 XX
 XX WO9622371-A2.
 XX 25-JUL-1996.
 XX 19-JAN-1996; 96MO-US00608.
 XX 19-JAN-1995; 95US-0375199.
 XX (BGM) BRIGHAM & WOMENS HOSPITAL.
 PA (CHIL-) CHILDRENS MEDICAL CENT.
 PA (LEOK-) LEUKOSITE INC.
 XX Gerard CJ, Gerard NP, Mackay CR, Ponath PD, Post TW;
 PI Qin S;
 PI
 XX WPI; 1996-354528/35.
 DR N-PSDB; AAT71336.
 DR
 XX Mammalian chemokine receptor-3 and related nucleic acids - useful to
 PT identify receptor inhibitors to treat inflammatory disease, e.g.
 PT autoimmune disorders, certain cancers, etc.
 XX
 XX Claim 10; Page 115-116; 153pp; English.
 PS
 XX A consensus amino acid sequence (AAW03378) was produced for a novel
 XX human receptor, designated Eos L2 or C-C chemokine receptor 2 (CCR-3).
 XX It was obt. by comparing the sequences (AAW03376-77) deduced from a
 XX CCR-3 genomic clone (AAT31334) and a cDNA clone (AAT31335). Initial
 XX sequence information revealed 2 regions in which the cDNA sequence
 XX appeared to be shifted in frame, resulting in 2 sets of 4 contiguous
 XX amino acid differences in the predicted proteins. Further sequence
 XX analysis revealed only a single difference between the 2 open
 XX reading frames, the genomic clone coding for threonine at position
 XX 276 and the cDNA clone for serine.
 SO
 Sequence 355 AA;
 Query Match 96.1%; Score 1781; DB 17; Length 355;
 Best Local Similarity 96.6%; Pred. No. 1.1e-192;
 Matches 343; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
 QY 1 MTSLDTVEFTGTTSTYDDVGLCEKADRALMAQFVPPPLYSLVFTVGLGNVVMYI 60
 DB 1 MTSLDTVEFTGTTSTYDDVGLCEKADRALMAQFVPPPLYSLVFTVGLGNVVMYI 60
 QY 61 KYRRLRIMNTIYLNLAIISDLFLVTLPMIHYVRGNVFGHGCKLLSGFYHTGLYSE 120
 DB 61 KYRRLRIMNTIYLNLAIISDLFLVTLPMIHYVRGNVFGHGCKLLSGFYHTGLYSE 120
 QY 121 IFFIILLTDRYLAIVHAVALPARKVTVGVTSITWGLAVLAALPEFIYETEELFEE 180
 DB 121 IFFIILLTDRYLAIVHAVALPARKVTVGVTSITWGLAVLAALPEFIYETEELFEE 180
 QY 181 TICSALYPEDTVYSMRHFTLRMTICLVLPILVMAICYGTIITLLRCPSSKKRYAIRL 240
 DB 181 TICSALYPEDTVYSMRHFTLRMTICLVLPILVMAICYGTIITLLRCPSSKKRYAIRL 240
 QY 241 IFVIMAVFIFMTPTVNAVALILSSYOSILFGNDCERSKHLDMVLTVEVLAISH-COMNPY 300
 DB 241 IFVIMAVFIFMTPTVNAVALILSSYOSILFGNDCERSKHLDMVLTVEVLAISH-COMNPY 300
 QY 301 IYAFVGERFRKYLHFFHRHLLMHLGRYIPFLPSEKLEKTSVSPSTAEPBELSIVF 355
 DB 301 IYAFVGERFRKYLHFFHRHLLMHLGRYIPFLPSEKLEKTSVSPSTAEPBELSIVF 355

RESURF 15
AAW51746
ID AAW51746 standard; Protein: 355 AA.
XX
AC AAW51746;
XX
DT 28-SEP-1998 (first entry)
XX
XX Human C-C chemokine receptor 3 consensus sequence.
XX
XX C-C chemokine receptor 3; CCR3; Eos 12; human;
XX G protein-coupled receptor; leukocyte; antibody; antagonist;
XX inflammation; allergy; asthma; graft rejection; infection;
XX autoimmune disease; drug screening; therapy.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX
XX Misc-difference 182 /note= "encoded by MTT"
XX Misc-difference 196 /note= "encoded by AGS"
XX Misc-difference 197 /note= "encoded by SAT"
XX Misc-difference 263 /note= "encoded by TSC"
XX Misc-difference 264 /note= "encoded by YMW"
XX Misc-difference 265 /note= "encoded by YMA"
XX Misc-difference 266 /note= "encoded by WTC"
XX Misc-difference 276 /note= "encoded by MMG"
XX Misc-difference 277 /note= "encoded by ARS"
XX Misc-difference 278 /note= "encoded by MYT"
XX Misc-difference 279 /note= "encoded by YNG"
XX Misc-difference 315 /note= "encoded by TTS"
XX
XX W09814480-A1.
XX
XX 09-APR-1998.
XX
XX 24-SEP-1997; 97WO-US17103.
XX
XX 30-SEP-1996; 96US-0720565.
XX
XX (LEUK-) LEUKOSITE INC.
XX
XX Mackay CR, Ponath PD;
XX
XX WPI: 1998-286418/25.
XX
XX N-PSDB: AAV07404.
XX
XX Antibodies to chemokine receptor-3 protein - useful for diagnosis
XX and treatment of inflammatory conditions, e.g. allergy, asthma,
XX autoimmune disease, graft rejection or cancer
XX
XX Disclousure: Page 138-139; 185pp; English.
XX
XX This amino acid sequence for human chemokine receptor-3 (CCR-3)
XX is deduced from a consensus nucleic acid sequence (see AAV07404)
XX constructed by alignment of a genomic DNA sequence (see AAV07402)
XX and a cDNA clone (see AAV07403) coding for CCR-3, a novel G
XX protein-coupled receptor that binds and mediates chemotaxis in
XX response to chemokines such as eotaxin, RANTES and MCP-3. Sequence
XX comparison revealed 2 regions in the cDNA sequence that appeared to
XX be shifted in frame, resulting from an insertion of a base followed

CC by the deletion of a base, or the deletion of a base followed by the
CC insertion of a base. These alterations resulted in 4 contiguous
CC amino acid differences in the predicted proteins (see AAW51744 and
CC AAW51745) at positions 263-266 and 276-279, respectively. In
CC addition, the genomic clone codes for threonine (ACG) at position
CC 276 and the cDNA clone for serine (AGC). CCR-3 nucleic acids,
CC polypeptides, antibodies, agonists and antagonists are useful for
CC diagnosis and treatment of inflammatory conditions, autoimmune
CC diseases and infections.
XX
XX SQ Sequence 355 AA;
XX
XX Query Match 96.1%; Score 1781; DB 19; Length 355;
XX Best Local Similarity 96.6%; Pred. No. 1.1e-192;
XX Matches 343; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
XX
XX 1 MTTSLDVEETGTSYVDVGLCKADTRALMOFVPLYSIVTVELLGNVVMILI 60
XX 1 MTTSLDVEETGTSYVDVGLCKADTRALMOFVPLYSIVTVELLGNVVMILI 60
XX
XX 61 KYRRLIMNTNIIYLLNLAISDLEFLVTLPEWIIHYVGNMVFSGHCKILSGFYHTGLYSE 120
XX 61 KYRRLIMNTNIIYLLNLAISDLEFLVTLPEWIIHYVGNMVFSGHCKILSGFYHTGLYSE 120
XX
XX 121 IFFIILLTIDRYLAIVHAVPALRARTVFGVITSIVTGLAVLAALPEFIYETEEELFEE 180
XX 121 IFFIILLTIDRYLAIVHAVPALRARTVFGVITSIVTGLAVLAALPEFIYETEEELFEE 180
XX
XX 181 TLCSALYEDPDVYSWRHPTLMTIFCGLVPLPLVAICYTGIIKTLCPSPKKKKAIRL 240
XX 181 TLCSALYEDPDVYSWRHPTLMTIFCGLVPLPLVAICYTGIIKTLCPSPKKKKAIRL 240
XX
XX 241 IFVIMAVPEIFMTVPYNAIILSSYOSILFGNDCERSKHLDLMLVTEVIYASHCCMPVI 300
XX 241 IFVIMAVPEIFMTVPYNAIILSSYOSILFGNDCERSKHLDLMLVTEVIYASHCCMPVI 300
XX
XX 301 YAFVGERRRKYLRFHFRHLLMHLGRYIPPLPSEKLETSVSPSTAPELSIVF 355
XX 301 YAFVGERRRKYLRFHFRHLLMHLGRYIPPLPSEKLETSVSPSTAPELSIVF 355
XX

Search completed: June 27, 2003, 18:12:30
Job time : 73 secs

